Patents by Inventor L. Wayne Schneider
L. Wayne Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9694021Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).Type: GrantFiled: November 20, 2013Date of Patent: July 4, 2017Assignee: ALCON RESEARCH, LTDInventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider
-
Publication number: 20150209466Abstract: The use of certain synthetic phospholipids to preserve pharmaceutical compositions from microbial contamination is described. The synthetic phospholipids have unique molecular arrangements wherein a phosphate group is linked to a quaternary ammonium functionality via a substituted-propenyl group, and the quaternary ammonium functionality is further linked to at least one long hydrocarbon chain. Such molecular arrangements are what make the phospholipids of formula (I) highly water soluble, e.g., the length of the hydrocarbon chain assists to maintain solubility and efficacy of the molecules for the uses described herein. The synthetic phospholipids described herein have been found to be particularly useful as antimicrobial preservatives for ophthalmic, otic and nasal pharmaceutical compositions, especially ophthalmic compositions. These compounds may also be utilized to disinfect contact lenses.Type: ApplicationFiled: February 19, 2015Publication date: July 30, 2015Applicant: ALCON RESEARCH, LTD.Inventors: Malay Ghosh, Masood A. Chowhan, L. Wayne Schneider
-
Publication number: 20140107121Abstract: The invention provides solution compositions comprising olopatadine and a PDE4 inhibitor compound of Formula I: The invention also provides methods for treating allergic and inflammatory diseases. More particularly, the present invention relates to formulations of olopatadine and their use for treating and/or preventing allergic or inflammatory disorders of the eye, nose, skin, and ear.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Applicant: Alcon Research, Ltd.Inventors: L. Wayne Schneider, Wesley Wehsin Han, Masood A. Chowhan
-
Publication number: 20140080793Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: Alcon Research, Ltd.Inventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider
-
Patent number: 8323630Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: GrantFiled: April 14, 2011Date of Patent: December 4, 2012Assignee: Alcon Research, Ltd.Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
-
Patent number: 8268299Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borat or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: GrantFiled: September 20, 2007Date of Patent: September 18, 2012Assignee: Alcon Research, Ltd.Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
-
Publication number: 20110269719Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).Type: ApplicationFiled: April 26, 2011Publication date: November 3, 2011Inventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider
-
Publication number: 20110195132Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: ApplicationFiled: April 14, 2011Publication date: August 11, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
-
Publication number: 20110124734Abstract: The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a contact lens comprising an N-halogenated amino acid and a phase transfer agent.Type: ApplicationFiled: January 31, 2011Publication date: May 26, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider, David W. Stroman, Nissanke L. Dassanayake
-
Publication number: 20110082145Abstract: The invention provides solution compositions comprising olopatadine and a PDE4 inhibitor compound of Formula I: The invention also provides methods for treating allergic and inflammatory diseases. More particularly, the present invention relates to formulations of olopatadine and their use for treating and/or preventing allergic or inflammatory disorders of the eye, nose, skin, and ear.Type: ApplicationFiled: October 1, 2010Publication date: April 7, 2011Applicant: ALCON RESEARCH, LTD.Inventors: L. Wayne Schneider, Wesley Wehsin Han, Masood A. Chowhan
-
Publication number: 20110071116Abstract: The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens.Type: ApplicationFiled: November 24, 2010Publication date: March 24, 2011Applicant: ALCON RESEARCH, LTD.Inventors: L. Wayne Schneider, Wesley Wehsin Han, Masood A. Chowhan, David W. Stroman, W. Dennis Dean, Michael S. Gaines
-
Publication number: 20100160342Abstract: The present invention relates to development of efficacious pharmaceutical compositions comprising an active agent, such as the free base or hydrochloride salt of tandospirone, for topical delivery to the eye for the treatment of retinal disorders.Type: ApplicationFiled: December 8, 2009Publication date: June 24, 2010Applicant: ALCON RESEARCH, LTD.Inventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider
-
Publication number: 20090197838Abstract: The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens.Type: ApplicationFiled: April 30, 2008Publication date: August 6, 2009Applicant: ALCON RESEARCH, LTD.Inventors: L. Wayne Schneider, Wesley Wehsin Han, Masood A. Chowhan, David W. Stroman, W. Dennis Dean, Michael S. Gaines
-
Publication number: 20080287395Abstract: The use of certain synthetic phospholipids to preserve pharmaceutical compositions from microbial contamination is described. The synthetic phospholipids have unique molecular arrangements wherein a phosphate group is linked to a quaternary ammonium functionality via a substituted-propenyl group, and the quaternary ammonium functionality is further linked to at least one long hydrocarbon chain. Such molecular arrangements are what make the phospholipids of formula (I) highly water soluble, e.g., the length of the hydrocarbon chain assists to maintain solubility and efficacy of the molecules for the uses described herein. The synthetic phospholipids described herein have been found to be particularly useful as antimicrobial preservatives for ophthalmic, otic and nasal pharmaceutical compositions, especially ophthalmic compositions. These compounds may also be utilized to disinfect contact lenses.Type: ApplicationFiled: May 16, 2008Publication date: November 20, 2008Applicant: ALCON RESEARCH, LTD.Inventors: Malay Ghosh, Masood A. Chowhan, L. Wayne Schneider
-
Publication number: 20080275121Abstract: The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a contact lens comprising an N-halogenated amino acid and a phase transfer agent.Type: ApplicationFiled: April 30, 2008Publication date: November 6, 2008Applicant: ALCON RESEARCH, LTD.Inventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider, David W. Stroman, Nissanke L. Dassanayake
-
Publication number: 20080093247Abstract: Packaging materials substantially lacking adsorptive and absorptive properties for 2-pyrrolidone derivatives are provided. The packaged products described herein provide for retention of the 2-pyrrolidone derivative within the formulation thereby maintaining the integrity of such formulations. Packaged products are useful for ophthalmic, otic, and nasal applications. Ophthalmic application includes therapeutic uses and contact lens care uses.Type: ApplicationFiled: October 24, 2007Publication date: April 24, 2008Applicant: Alcon Manufacturing Ltd.Inventors: Wesley Wehsin Han, Masood A. Chowhan, Jang-Shing Chiou, L. Wayne Schneider, Bhagwati P. Kabra
-
Patent number: 6429227Abstract: HETE salts, the preparation of HETE salts, the preparation of stable and efficacious HETE compositions, HETE compositions and methods of use for treating dry eye are disclosed.Type: GrantFiled: October 23, 2000Date of Patent: August 6, 2002Assignee: Alcon Universal Ltd.Inventors: L. Wayne Schneider, Raymond E. Conrow, Daniel A. Gamache, Terri Pasquine, John M. Yanni, Haresh G. Bhagat
-
Patent number: 6353022Abstract: Compositions containing one or more HETE derivative(s) and an effective concentration of ethanol and methods of use for treating dry eye are disclosed.Type: GrantFiled: October 23, 2000Date of Patent: March 5, 2002Assignee: Alcon Universal Ltd.Inventors: L. Wayne Schneider, Daniel A. Gamache, Lori K. Weimer, Timothy L. Kessler, Zhongyou Wei, Terri Pasquine, John M. Yanni, Haresh G. Bhagat
-
Patent number: 6011062Abstract: The use of polyethoxylated castor oils in prostaglandin compositions enhances the prostaglandin's chemical stability.Type: GrantFiled: February 9, 1999Date of Patent: January 4, 2000Assignee: Alcon Laboratories, Inc.Inventors: L. Wayne Schneider, Rajan Bawa, Alan L. Weiner
-
Patent number: 5849792Abstract: The use of polyethoxylated castor oils in prostaglandin compositions greatly enhances the prostaglandin's chemical stability.Type: GrantFiled: October 29, 1996Date of Patent: December 15, 1998Assignee: Alcon Laboratories, Inc.Inventor: L. Wayne Schneider